⌘+K

News

11%-point Y/Y margin improvement - Q4 initial comment

Kristofer Liljeberg

Elvin Rolder

2026-02-12

08:20 CET

Overall impressions. Q4 was a solid report from Carasent. Revenue was SEK94m, which was 1% above our forecast, and the organic growth was 16% Y/Y, in tune with us. The implementation of Volvat in Q4 has progressed well according to the company, with only two smaller systems remaining to migrate. The organic ARR growth in Q4 was 15% and by the end of Q4, ARR was SEK326m, with SEK5m in signed not yet implemented ARR. The decline in signed not implemented ARR Q/Q primarily pertains to the Volvat transitioning to actual ARR instead non-implemented. The gross margin in Q4 was somewhat lower than we anticipated driven by a slightly bigger impact from the one-off sales in Germany than we expected, but this is isolated to Q4, we believe. Costs and the degree of capitalised development were slightly lower than expected. Hence, adj. EBITDAC was SEK14.5m, 3% above our expectation, albeit negligible deviation in absolute terms. Q4 adj. EBITDAC margin was 15.5%, 30bps higher than our expectations, and a 11%-point improvement Y/Y. For the full year, adj. EBITDAC margin reached close to 10%, and the margin journey has started to unfold, with plenty of room left to scale profitability the coming years with today’s figures reinforcing that notion, we believe.

Estimates. Given the overall in line numbers in Q4, we would expect limited consensus changes.

Share price reaction. The share price has slumped YTD, falling >15%. While today’s figures are unlikely to trigger any meaningful estimate revisions, we believe the continued margin scaling, and close to complete implementation of Volvat should trigger a slight positive share price reaction of 2–4%.

Sweden

Healthcare

Latest share price

SEK

25.2

-0.98%

18 Nov 2026 15:45 CET

Fair value range

SEK

33.0

—

44.0

24 Jun 2026

Market cap

SEK

1,788

m

Next report

Q4

4 Feb 2027

Key stats

Year

2026e

EPS

0.39

EPS (Adj.)

0.62

Sales Growth

20.48%

EPS Growth (Adj.)

99.37%

P/E

64.5

P/E (Adj.)

41.0

EV/EBITA

52.9

EV/EBITDA

19.5

Learn more

About DNB Carnegie Access

DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.

Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.

Private Banking

Tailored wealth management. Your financial future, personalized.

Montrose

A digital investment platform designed for passionate investors.

DNB Carnegie

Leading Nordic investment bank and wealth management.

© Copyright DNB Carnegie Investment Bank AB